INCREASES LOCAL MANUFACTURING, JOBS AND EXPORTVOLUME
LAVAL, QC, June 7, 2016 /CNW/ - Valeant Canada today announced that it is further building on its commitment to Canadian manufacturing and export with the transfer of the North American production of Arestin, an antibiotic treatment for periodontal (gum) disease, to Laval, Quebec.
The transfer involves an additional investment of $2.5 million and will create 15 new engineering and production jobs. The announcement was made at the BIO International Convention in the presence of the Quebec Minister of Economy, Science and Innovation, Mrs. Dominique Anglade, as well as the Mayor of the city of Laval, Mr. Marc Demers.
"Today's announcement is great news for the manufacturing sector in Quebec, showing Valeant Canada's commitment in this area. The innovative manufacturing sector and its impact in terms of exports, is one of the pillars of our vision for the economic development of Quebec, "said Minister Dominique Anglade.
Since 2012, Valeant has steadily and consistently transferred technologies to its Laval facility for manufacture, for a total of 67 new products.
"Following the announcement earlier this year that the U.S. production of Jublia® has been established in Quebec, our Laval facility has once again been selected as a production site for the US market due to its operational effectiveness good reputation, competitive environment convenient location, and. We are committed to continuing to invest in Quebec's thriving biotechnology sector," said Jacques Dessureault, President and General Manager of Valeant Canada.
The $2.5 million investment for Arestin supports enabling a precise production method, including the construction of specialized rooms fitted with electrical power conditioning and reinforced concrete to ensure a vibration-free zone. It is in these rooms that the product is carefully fed into cartridges before being placed on a specialized checkweigher. Fifteen new high value jobs, such as engineers, will be created to support the Laval plant's expanded manufacturing mandate.
"With the announcement of this investment in its Laval manufacturing centre, Valeant Canada is proving itself once again to be a key partner in the ongoing development of Laval's and Quebec's life sciences ecosystems," said Marc Demers, Mayor of Laval.
Valeant's Laval manufacturing site currently exports 75% of its local production to the United States and other countries. As a local manufacturing organization, Valeant's Laval site is proud to source 78% of its ingredients from local suppliers.
About Peridontal (Gum) Disease, Arestin®
Nearly one in every two adults in the US age 30 and over suffers from gum disease.1 In Canada, seven out of ten people will develop gum disease at some point in their lives.2 Arestin® is an antibiotic treatment for periodontal (gum) disease that is used as an add‐on therapy to dental scaling and root planning (SRP) procedures to treat patients with adult periodontitis (gum disease).
About Valeant Canada
Valeant Canada is a subsidiary of Valeant Pharmaceuticals International Inc., a multinational specialty pharmaceutical company that develops, manufactures, and markets a broad range of pharmaceutical products, primarily in the areas of dermatology, eye health, cardio-metabolic, and neurology. More information about Valeant Canada can be found at www.valeantcanada.com.
SOURCE Valeant Canada
For further information: Sébastien Beauchamp, Valeant Canada LP, Tel. : 514-744-6792, Courriel : email@example.com